Details of the Drug Combinations

General Information of This Drug (ID: DM16RIC)

Drug Name

Oprozomib DM16RIC

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 2	[1]
Haematological malignancy	2B33.Y	Phase 1/2	[2]
Multiple myeloma	2A83	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Oprozomib + Panobinostat	DCDOD3Y	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Oprozomib + Marizomib	DC5Z4TZ	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Oprozomib + Ruxolitinib	DCJMRQP	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[6]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01832727) Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.